Kiadis Pharma rais­es €23.4 mil­lion in a pri­vate place­ment of 2.6 mil­lion new shares

Amsterdam, The Netherlands, March 13, 2018 – Kiadis Pharma N.V. (“Kiadis Pharma” or the “Company”) (Euronext Amsterdam and Brussels: KDS), a clin­i­cal stage bio­phar­ma­ceu­ti­cal com­pa­ny devel­op­ing a T-cell immunother­a­py prod­uct designed to reduce Graft ver­sus Host Disease (GVHD) in hematopoi­et­ic stem cell trans­plan­ta­tions (HSCT), today announces that it has raised gross pro­ceeds of €23.4 mil­lion through a pri­vate place­ment of 2.6 mil­lion new shares to insti­tu­tion­al investors via an accel­er­at­ed book­build­ing process as announced on March 12, 2018 (the “Placing”). The Placing was com­plet­ed at a sub­scrip­tion price of €9.00 per share and rep­re­sent­ed 14.8% of the issued share cap­i­tal of the Company pri­or to the trans­ac­tion. The new ordi­nary shares will rank pari pas­su in all respects with the cur­rent­ly out­stand­ing shares of the Company and are expect­ed to be list­ed and trad­ed on Euronext Amsterdam and Euronext Brussels on March 15, 2018. Following the Placing, the issued share cap­i­tal of the Company will con­sist of 20,115,092 ordi­nary shares.
Arthur Lahr, CEO of Kiadis Pharma, com­ment­ed: “This €23.4 mil­lion pri­vate place­ment will fund the Company into H2 2019 and thus well beyond poten­tial EU approval and into poten­tial European launch of ATIR101TM. The offer­ing was over­sub­scribed and allowed us to make full use of the remain­ing author­i­ty to issue new shares as grant­ed by the share­hold­ers. Strong inter­est from exist­ing and new spe­cial­ized biotech investors from Europe and the US fur­ther val­i­dates Kiadis Pharma’s great progress and poten­tial. With more than €60 mil­lion raised in the last 10 months, we have now suc­cess­ful­ly financed the Company towards major near-term mile­stones.

Kiadis Pharma intends to use the net pro­ceeds of the Placing to:
– con­tin­ue the Phase 3 inter­na­tion­al, ran­dom­ized, con­trolled, mul­ti­cen­tre clin­i­cal tri­al for ATIR101 in the United States, Canada and Europe;
– gen­er­ate addi­tion­al man­u­fac­tur­ing capac­i­ty at ven­dors and to refur­bish, equip and staff its leased man­u­fac­tur­ing facil­i­ty;
– fur­ther pre­pare the Company for com­mer­cial­iza­tion by invest­ing into a com­mer­cial orga­ni­za­tion,
– mar­ket access prepa­ra­tion and reim­burse­ment dis­cus­sions;
– sup­port fur­ther pro­duc­tion process opti­miza­tion of ATIR;
– expand the orga­ni­za­tion to accom­mo­date the increased num­ber of activ­i­ties;
– start a fur­ther clin­i­cal tri­al to assess the ben­e­fit of ATIR101 in con­junc­tion with anoth­er T-cell deplet­ed hematopoi­et­ic stem cell trans­plan­ta­tion (HSCT) pro­to­col or with a cyclophos­phamide-based hap­loiden­ti­cal trans­plan­ta­tion pro­to­col;
– apply funds for debt repay­ment, cap­i­tal expen­di­tures, gen­er­al and admin­is­tra­tive expens­es, gen­er­al cor­po­rate pur­pos­es in line with Kiadis Pharma’s strat­e­gy and oth­er work­ing cap­i­tal needs; and
– finance poten­tial oppor­tu­ni­ties to broad­en and diver­si­fy the research and devel­op­ment port­fo­lio (e.g. through in-licens­ing or acquir­ing pro­grams and com­pa­nies with syn­er­gis­tic or com­ple­men­tary tech­nolo­gies, prod­ucts and/or prod­uct can­di­dates).

Jefferies International Limited act­ed as Sole Bookrunner, Canaccord Genuity Limited as Lead Manager, Chardan as Co-Lead Manager and LifeSci Capital LLC as Co-Manager in con­nec­tion with the Placing. Saola Healthcare Partners act­ed as finan­cial advi­sor to the Company.